Grisel J Lopez

List of Publications by Citations

33 papers	1,416 citations	13 h-index	34 g-index
34 ext. papers	1,807 ext. citations	6.5 avg, IF	4.52 L-index

#	Paper	IF	Citations
33	The link between the GBA gene and parkinsonism. *Lancet Neurology, The*, **2012**, 11, 986-98	24.1	353
32	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurology*, **2013**, 70, 727-35	17.2	285
31	A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. *Journal of Neuroscience*, **2016**, 36, 7441-52	6.6	150
30	The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. *Archives of Neurology*, **2008**, 65, 1353-7		142
29	Gaucher disease: Progress and ongoing challenges. *Molecular Genetics and Metabolism*, **2017**, 120, 8-21	3.7	72
28	Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. *Science Translational Medicine*, **2014**, 6, 240ra73	17.5	72
27	The clinical management of Type 2 Gaucher disease. *Molecular Genetics and Metabolism*, **2015**, 114, 110-122	3.7	71
26	The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. *Brain*, **2012**, 135, 2440-8	11.2	67
25	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
24	Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 50, 108-112	3.6	28
23	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. *Neurology: Genetics*, **2016**, 2, e57	3.8	23
22	Cardiac sympathetic denervation predicts PD in at-risk individuals. *Parkinsonism and Related Disorders*, **2018**, 52, 90-93	3.6	20
21	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. *Molecular Genetics and Metabolism*, **2020**, 130, 164-169	3.7	14
20	Autosomal recessive mutations in the development of Parkinson's disease. *Biomarkers in Medicine*, **2010**, 4, 713-21	2.3	11
19	Variation in cognitive function over time in Gaucher disease type 3. *Neurology*, **2019**, 93, e2272-e2283	6.5	10
18	Efferocytosis is impaired in Gaucher macrophages. *Haematologica*, **2017**, 102, 656-665	6.6	8
17	The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. *Neurology*, **2020**, 95, e2119-e2130	6.5	8

List of Publications

16	Alleles with more than one mutation can complicate genotype/phenotype studies in Mendelian disorders: Lessons from Gaucher disease. *Molecular Genetics and Metabolism*, **2018**, 125, 1-3	3.7	8
15	Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?. *Movement Disorders*, **2020**, 35, 228-230	7	6
14	Clinical evaluation of sibling pairs with gaucher disease discordant for parkinsonism. *Movement Disorders*, **2020**, 35, 359-365	7	6
13	Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism. *Trends in Molecular Medicine*, **2020**, 26, 913-923	11.5	6
12	Five-parameter evaluation of dysphagia: A novel prognostic scale for assessing neurological decline in Gaucher disease type 2. *Molecular Genetics and Metabolism*, **2019**, 127, 191-199	3.7	5
11	Type 2 Gaucher disease in an infant despite a normal maternal glucocerebrosidase gene. *American Journal of Medical Genetics, Part A*, **2017**, 173, 3211-3215	2.5	4
10	EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. *Molecular Genetics and Metabolism*, **2020**, 131, 358-363	3.7	4
9	Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations. *Annals of Neurology*, **2020**, 87, 652-657	9.4	3
8	Bilateral Femoral Osteolytic Lesions in a Patient with Type 3 Gaucher Disease. *Molecular Genetics and Metabolism Reports*, **2015**, 5, 107-109	1.8	3
7	Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter?. *Journal of Xiangya Medicine*, **2018**, 3, 1-1	0.1	3
6	No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.. *Movement Disorders*, **2022**,	7	2
5	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. *Expert Opinion on Orphan Drugs*, **2015**, 3, 549-562	1.1	1
4	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. *International Journal of Molecular Sciences*, **2022**, 23, 5842	6.3	0
3	Studies of glucocerebrosidase provide new therapeutic targets for parkinsonism. *Future Neurology*, **2014**, 9, 407-409	1.5	
2	Gaucher Disease and Heart Failure of Unknown Origin. *American Journal of Medicine*, **2021**, 134, 745-748	2.4	
1	Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation. *Journal of Neurology*,	5.5	